Search results
Showing 2056 to 2070 of 2579 results for methods
In development Reference number: GID-TA11433 Expected publication date: TBC
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
Discontinued Reference number: GID-TA10402
In development Reference number: GID-TA11299 Expected publication date: TBC
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]
Discontinued Reference number: GID-TA10045
Discontinued Reference number: GID-TA10543
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]
Discontinued Reference number: GID-TA10341
HemaClear for bloodless surgical field during limb surgery (MIB187)
NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
NICE has developed a medtech innovation briefing (MIB) on Acumen IQ sensor for predicting hypotension risk .
NICE has developed a medtech innovation briefing (MIB) on Cor-Knot for tying suture knots in valve surgery .
NPi-200 for pupillary light reflex in critical care patients (MIB235)
NICE has developed a medtech innovation briefing (MIB) on NPi-200 for pupillary light reflex in critical care patients .
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Masitinib for treating amyotrophic lateral sclerosis [ID967]
Discontinued Reference number: GID-TA10157
Discontinued Reference number: GID-TA10171